What Private Equity Sees in Diagnostics

By Scott Wallask | From the Volume XXXII, No. 16 – November 17, 2025 Issue

CEO SUMMARY: Hologic’s acquisition by private equity firms Blackstone and TPG marks one of the year’s largest in vitro diagnostics transactions and a clear vote of confidence in the sector’s resilience. Industry analyst Bruce Carlson unpacks what the buyout …

Read More

---

August 25, 2025, Intelligence: Late-Breaking Lab News

By Scott Wallask | From the Volume XXXII, No. 12 – August 25, 2025 Issue

As we first reported in Dark Daily earlier this month, several states have taken initiative to regulate how artificial intelligence (AI) applies to clinical laboratory services. For example, a California law that went into effect earlier this year impacts providers who use gene…

Read More

---

IVD Firms Prepare for OTC, Home Test Market Expansion

By Robert Michel | From the Volume XXX, No. 6 – April 17, 2023 Issue

CEO SUMMARY: With public interest in home testing growing, some IVD manufacturers are preparing to serve a fast-expanding market for over-the-counter and at-home tests. IVD firms are banking on the…

Read More

---

Reports Say Qiagen and Bio-Rad Discussing Potential IVD Merger

By Scott Wallask | From the Volume XXIX, No. 15 – October 31, 2022 Issue

More consolidation in the in vitro diagnostics (IVD) mar­ket may soon happen. Bio-Rad Laboratories and Qiagen are reportedly in merger discussions. The Wall Street Journal, which broke the story on Oct. 10, tabbed the potential deal as being worth …

Read More

---

In Post-COVID-19 Market, IVD Manufacturers Face Supply, Staff Challenges

By Robert Michel | From the Volume XXIX, No. 10 – July 18, 2022 Issue

CEO SUMMARY: After making billions during the COVID-19 pandemic, in vitro diagnostics (IVD) manufacturers must now adjust their strategies and relationships with clinical laboratory customers. Because many contracts for automated instruments are coming due, some IVD companies have t…

Read More

---